DoD Gulf War Illness, Idea Award | W81XWH 21 GWIRP IA

Opportunity Information: Apply for W81XWH 21 GWIRP IA

The DoD Gulf War Illness Research Program (GWIRP) FY21 Idea Award is a research grant opportunity designed to spark brand-new, early-stage ideas that could eventually lead to meaningful biomarkers (markers) or treatments for Gulf War Illness (GWI) affecting Veterans of the 1990-1991 Gulf War. It is specifically aimed at the Discovery phase of the research pipeline, meaning the program is looking for projects that are still in the formative stages but have a strong scientific rationale and clear potential to open up new directions for the field. The emphasis is on innovation and creativity, including high-risk/high-reward approaches that may challenge existing thinking, introduce a new framework for understanding GWI, or apply fresh perspectives to long-standing problems. Multidisciplinary projects are especially encouraged, reflecting the reality that GWI symptoms cut across many biological systems and often require expertise from multiple fields to study effectively.

A notable feature of this award is that preliminary data are not required. The program is structured to lower the barrier for proposing bold concepts that might not yet have extensive supporting datasets. If applicants do include unpublished preliminary results, those data are expected to come from the principal investigator or the project team. Even without preliminary data, proposals must still be grounded in a sound scientific rationale, supported by logical reasoning and/or a strong, critical review of existing research literature. In other words, the program is willing to fund early ideas, but it still expects the underlying reasoning to be credible and well-supported.

The program also places a strong requirement on impact. Every application must clearly explain how the expected results could lead to clinical benefit for Veterans with GWI, even if the work itself will not immediately produce a clinical tool or therapy. The focus must remain explicitly on Gulf War Illness and the population of Veterans from the 1990-1991 Gulf War affected by GWI. Applicants are expected to make the case, in plain terms, for how their project could matter to GWI specifically, rather than broadly addressing related conditions without a direct connection.

While applicants can propose work in any GWI-relevant area aligned with the program mission, the FY21 Idea Award highlights several areas of special interest. These include identifying treatments for GWI, especially approaches that already show signs of benefit, and identifying causes and treatment targets tied to dysregulated biological systems. The announcement lists a wide range of symptom and system domains that are of interest, such as cognitive and mood-related difficulties (including memory deficits and behavior disturbances), non-restorative sleep and sleep disorders, chronic widespread pain, chronic debilitating fatigue, gastrointestinal issues (including dietary intolerances, GERD, and functional GI disorders), sinus and respiratory effects, headaches, dermatological problems, neurological dysfunction (central, peripheral, autonomic, and neuromuscular), immune dysfunction, and endocrine/exocrine/excretory dysfunction with particular attention to kidney and liver pathways (including cytochrome P450 abnormalities). It also encourages research on microbiome variants, how stressors like exertion or immune challenge influence symptom severity and duration, and how dysfunctional "crosstalk" between systems (for example, immune changes affecting the nervous system, or autonomic dysfunction disrupting GI function) can drive multi-system illness. Additional emphasized directions include identifying molecular signatures (genomic, proteomic, metabolic, epigenetic) that may explain symptoms and help subgroup patients by underlying biology, studying comorbidities and differences by sex or ethnicity, evaluating whether GWI changes outcomes for other infections or diseases, and developing treatments or biomarkers tailored to specific GWI subtypes.

The opportunity also includes an optional Biorepository Contribution pathway tied to the Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI, which was created to retain and share biospecimens and data from Gulf War Veterans for research use. Applicants are encouraged to contribute relevant Veteran biospecimens and/or data to this network, and those who apply under the Biorepository Contribution Option can request slightly higher funding. This option comes with extra submission requirements (including a specific biorepository contribution statement) and is intended to strengthen shared research infrastructure and improve the long-term value of funded projects for the broader GWI research community.

Several activities are explicitly not supported. The program will not fund studies that treat psychiatric disease or psychological stress as the primary cause of GWI. It also does not support applications focused on amyotrophic lateral sclerosis (ALS) as the central topic, although Gulf War Veterans with ALS may be included if ALS is part of the study's GWI case definition and the work is still fundamentally about GWI symptomatology. In addition, clinical trials are not allowed under this mechanism. For this program, a clinical trial is defined as prospective assignment of human subjects to interventions (including placebo or controls) to evaluate effects on health outcomes. Researchers who want to run clinical trials are directed to other GWIRP funding mechanisms designed for that purpose, such as the Clinical Evaluation Award or Therapeutic/Biomarker Trial Award.

From an administrative standpoint, awards are issued as federal assistance agreements, meaning they can be either grants or cooperative agreements depending on how much involvement the Department of Defense expects to have during the project. If the agency anticipates no substantial involvement, a standard grant is used; if substantial involvement is expected (such as collaboration or participation in aspects of the research), a cooperative agreement is used, and the specific involvement is spelled out in the award terms. The funding limit for the Idea Award is capped at $200,000 in direct costs for the full period of performance, or up to $220,000 in direct costs if using the Biorepository Contribution Option. The program anticipated making about one award, with an estimated total allotment of about $0.32 million, and awards were expected to be made by September 30, 2022. Eligibility is listed as unrestricted (open to any entity type, subject to any additional eligibility notes in the full announcement). The opportunity was administered by the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA), under funding opportunity number W81XWH-21-GWIRP-IA, with the original application closing date of August 19, 2021.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, Idea Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 11, 2021.
• Applicants must submit their applications by Aug 19, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 GWIRP IA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: